CEO Soriot said Europe must boost investment in pharma innovation or risk falling further behind the US in drug development.

Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro ...

AstraZeneca has axed three MedImmune legacy monoclonal antibody drugs from its neuroscience pipeline in a first-quarter clear ...

LONDON (Reuters) -The chief executive of AstraZeneca said on Tuesday that the drugmaker will maintain its 2025 sales guidance ...

The logo of US pharmaceutical company Pfizer at the 7th China International Import Expo in Shanghai, on Nov 7, 2024. [Photo/VCG] BEIJING - US pharmaceutical giant Pfizer's new research and development ...

IgA nephropathy (IgAN) is an autoimmune disorder that affects the kidneys by impairing the filtration function of the small ...

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today ...

By Maggie Fick LONDON (Reuters) -AstraZeneca Chief Executive Officer Pascal Soriot said on Wednesday that just like Europe ...

CEO Pascal Soriot said Europe was "falling behind" in attracting investment and needed to "invest more in what really matters ...

This decision follows the British drugmaker's announcement last year of a $3.5 billion investment in the United States aimed ...